PROCEPT BioRobotics Corporation Class Action Lawsuit - PRCT

PROCEPT BioRobotics Corporation
NASDAQ: PRCT

Affected PRCT Investor Summary

- **Who:** PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
- **What:** Securities fraud class action lawsuit filed
- **Class Period:** February 28, 2024 through February 25, 2026
- **Deadline to Seek Lead Plaintiff Status:** September 22, 2026
- **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's product demand
- **Investor Action:** Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options

The *PROCEPT BioRobotics Corporation* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *PROCEPT BioRobotics Corporation* ("*PROCEPT*") (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). Captioned *Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation,* No. 26-cv-07691 (N.D. Cal.), the *PROCEPT* class action lawsuit alleges that *PROCEPT* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *PROCEPT* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than September 22, 2026.

COMPLAINT ALLEGATION SUMMARY:

PROCEPT is a commercial stage medical technology company focused primarily on the treatment of benign prostatic hyperplasia ("BPH"), also known as an enlarged prostate. One of the devices that *PROCEPT* manufactured and sold for the treatment of BPH was an Aquablation therapy system that utilized a single-use handpiece that was disposed of after the procedure.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) *PROCEPT* utilized a discount program to incentivize customers to place bulk orders in excess of demand; (2) the undisclosed discount program artificially inflated the company's reported U.S. handpiece unit sales; (3) the consistent surplus of U.S. handpiece unit sales results in overstocking and exposed *PROCEPT* to material undisclosed risks of operational and financial harm; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID PROCEPT'S STOCK DROP?
On February 25, 2026, *PROCEPT* announced its financial earning for the year 2025 and the first quarter of 2026. Specifically, *PROCEPT* revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, despite consistent reassurances to the contrary. On this news, the price of *PROCEPT's* common stock fell more than 18%.

THE LEAD PLAINTIFF PROCESS:
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *PROCEPT* common stock during the Class Period to seek appointment as lead plaintiff in the *PROCEPT* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.